Silence Therapeutics Plc Stock Shares Owned By Institutions
| SLN Stock | USD 7.21 0.20 2.85% |
Silence Therapeutics PLC fundamentals help investors to digest information that contributes to Silence Therapeutics' financial success or failures. It also enables traders to predict the movement of Silence Stock. The fundamental analysis module provides a way to measure Silence Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Silence Therapeutics stock.
Silence | Shares Owned By Institutions |
Silence Therapeutics PLC Company Shares Owned By Institutions Analysis
Silence Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Silence Therapeutics Shares Owned By Institutions | 62.70 % |
Most of Silence Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Silence Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Silence Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Silence Therapeutics is extremely important. It helps to project a fair market value of Silence Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Silence Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Silence Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Silence Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 62% of Silence Therapeutics PLC are shares owned by institutions. This is 40.46% higher than that of the Biotechnology sector and 32.0% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 59.91% lower than that of the firm.
Silence Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Silence Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Silence Therapeutics could also be used in its relative valuation, which is a method of valuing Silence Therapeutics by comparing valuation metrics of similar companies.Silence Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
Silence Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Silence Therapeutics from analyzing Silence Therapeutics' financial statements. These drivers represent accounts that assess Silence Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Silence Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 368.2M | 438.9M | 523.4M | 405.9M | 506.6M | 531.9M | |
| Enterprise Value | 355.0M | 411.8M | 450.0M | 351.5M | 452.9M | 475.5M |
Silence Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Silence Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Silence Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Silence Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.24) % | ||||
| Operating Margin | (30.64) % | ||||
| Current Valuation | 616.9 M | ||||
| Shares Outstanding | 47.21 M | ||||
| Shares Owned By Insiders | 16.93 % | ||||
| Shares Owned By Institutions | 62.70 % | ||||
| Number Of Shares Shorted | 353.32 K | ||||
| Price To Book | 2.78 X | ||||
| Price To Sales | 43.52 X | ||||
| Revenue | 25.38 M | ||||
| Gross Profit | 6.62 M | ||||
| EBITDA | (49.78 M) | ||||
| Net Income | (50.31 M) | ||||
| Cash And Equivalents | 51.56 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 272 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.76 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (39.35 M) | ||||
| Short Ratio | 2.36 X | ||||
| Earnings Per Share | (1.69) X | ||||
| Target Price | 53.7 | ||||
| Number Of Employees | 109 | ||||
| Beta | 1.29 | ||||
| Market Capitalization | 779.04 M | ||||
| Total Asset | 93.82 M | ||||
| Retained Earnings | (304.61 M) | ||||
| Working Capital | 63.25 M | ||||
| Net Asset | 93.82 M |
About Silence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Silence Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Silence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Silence Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Silence Stock
| 0.71 | ME | 23Andme Holding | PairCorr |
| 0.66 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Silence Stock
| 0.62 | RNXT | RenovoRx | PairCorr |
| 0.57 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.45 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Silence Therapeutics Piotroski F Score and Silence Therapeutics Altman Z Score analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.